Vanguard Group Inc Corvus Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,420,619 shares of CRVS stock, worth $19.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,420,619

Previous 1,650,500 46.66%

Holding current value

$19.8 Million

Previous $3 Million 325.57%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.78 - $5.92 $1.37 Million - $4.56 Million	770,119 Added 46.66%	2,420,619 $12.8 Million
Q2 2024 Aug 13, 2024	BUY	$1.36 - $2.29 $213,714 - $359,857	157,143 Added 10.52%	1,650,500 $3 Million
Q1 2024 May 10, 2024	BUY	$1.76 - $2.41 $251,194 - $343,964	142,724 Added 10.57%	1,493,357 $2.66 Million
Q4 2023 Feb 14, 2024	BUY	$1.08 - $1.92 $3,997 - $7,105	3,701 Added 0.27%	1,350,633 $2.38 Million
Q3 2023 Nov 14, 2023	BUY	$1.41 - $2.97 $64,446 - $135,749	45,707 Added 3.51%	1,346,932 $1.97 Million
Q2 2023 Aug 14, 2023	BUY	$1.0 - $3.86 $40,659 - $156,943	40,659 Added 3.23%	1,301,225 $2.98 Million
Q4 2022 Feb 10, 2023	BUY	$0.74 - $1.04 $488 - $686	660 Added 0.05%	1,260,566 $1.07 Million
Q3 2022 Nov 14, 2022	SELL	$0.71 - $1.17 $5,570 - $9,179	-7,846 Reduced 0.62%	1,259,906 $1.03 Million
Q1 2022 May 13, 2022	BUY	$1.46 - $2.48 $52,562 - $89,284	36,002 Added 2.92%	1,267,752 $2.08 Million
Q4 2021 Feb 14, 2022	BUY	$2.34 - $5.31 $66,425 - $150,734	28,387 Added 2.36%	1,231,750 $2.97 Million
Q3 2021 Nov 12, 2021	BUY	$1.89 - $8.53 $177,934 - $803,056	94,145 Added 8.49%	1,203,363 $5.82 Million
Q2 2021 Aug 13, 2021	BUY	$2.46 - $3.14 $2.73 Million - $3.48 Million	1,109,218 New	1,109,218 $2.96 Million

Others Institutions Holding CRVS

# of Institutions

Shares Held

30.4M

Call Options Held

1.06M

Put Options Held

84.3K

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $381M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Corvus Pharmaceuticals, Inc. Transaction History